跳至主要内容
临床试验/RPCEC00000418
RPCEC00000418尚未招募1 期

Safety evaluation and preliminary effect of the monoclonal antibody Nimotuzumab in the treatment of patients with acute respiratory distress syndrome (ARDS)

Center of Molecular Immunology (CIM)0 个研究点目标入组 74 人开始时间: 2023年3月3日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
19 years 至 none(—)
性别
All

入选标准

  • 1. Mild or moderate ARDS, with subpulmonary or extrapulmonary phenotype.
  • 2. Any gender and skin color
  • 3. Age equal to or greater than 19 years
  • 4. Patients with signed informed consent

排除标准

  • 1 Pregnancy or breastfeeding.
  • 2. History of known HIV, hepatitis B or C infection (referred by the patient or their representative).
  • 3 Known allergy or hypersensitivity to any component of the formulation under study.
  • 4. Minimal probability of survival and a life expectancy of less than 3-5 days as defined by an APACHE II score of = 35 at enrollment.
  • 5 Be receiving another investigational product.

研究者

发起方
Center of Molecular Immunology (CIM)

相似试验